Pharmacotherapy of abdominal aortic aneurysms

Current Vascular Pharmacology

Volumn 4, Issue 2, 2006, Pages 129-149

  Dawson, Joe ^a   Choke, Edward ^a   Sayed, Saiqa ^a   Cockerill, Gillian ^a   Loftus, Ian ^a   Thompson, Matt M ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Abdominal; Aneurysm; Aortic; Management; Medical; Pharmacology; Pharmacotherapy

Indexed keywords

ANGIOTENSIN II; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BATIMASTAT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHYMASE INHIBITOR; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; HYDRALAZINE; HYDROXAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; MATRIX METALLOPROTEINASE INHIBITOR; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENELZINE; PLASMINOGEN ACTIVATOR INHIBITOR; PRACTOLOL; PROPRANOLOL DERIVATIVE; PROTEINASE INHIBITOR; RAPAMYCIN; RESPERPINE; SIMVASTATIN; SOLTALOL; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT;

ABDOMINAL AORTA ANEURYSM; ABDOMINAL SURGERY; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMOOTH MUSCLE FIBER; THROMBUS; UNITED KINGDOM; VASCULAR SMOOTH MUSCLE; ANIMAL; PATHOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; AORTIC ANEURYSM, ABDOMINAL; CLINICAL TRIALS; HUMANS; PROTEASE INHIBITORS;

EID: 33646033786     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106776359817     Document Type: Review

References (248)

1. Johnson KW, Rutherford RB, Tilson MD, Shah DM, Hollier L, Stanley JC. Suggested standards for reporting on arterial aneurysms. J Vasc Surg 1991; 13: 452-8.
2. Thompson MM, Bell PRF. Arterial aneurysms. Br Med J 2000; 320: 1193-1197.
3. Bickerstaff LK, Hollier LH, Van Peenen HJ, Melton LJI, Pairolero PC, Cherry KJ. Abdominal aortic aneurysms: the changing natural history. J Vasc Surg 1984; 1: 6-12.
4. Walling AD. What happens to small abdominal aortic aneurysms? Am Fam Physician 2002; 65: 2128-30.
5. Lederle FA, Johnson GR, Wilson SE, Ballard DJ, Jordon WDJ, Blebea J, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective surgery. JAMA 2002; 287: 2968-72.
6. Glimaker H, Holmberg L, Elvin A, Nybacka O, Almgren B, Bjorck CG, et al. Natural history of patients with abdominal aortic aneurysm. Eur J Vasc Surg 1991; 5: 125-30.
7. Guirguis EM, Barber GG. The natural history of abdominal aortic aneurysms. Am J Surg 1991; 162: 481-3.
8. Ingoldby CJ, Wujanto R, Mitchell JE. Impact of vascular surgery on community mortality from ruptured aortic aneurysms. Br J Surg 1986; 73: 551-3.
9. Lindholt JS, Vammen S, Juul S, Henneberg EW, Fasting H. The validity of ultrasonographic scanning as screening method for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 1999; 17: 472-5.
10. MacSweeney ST, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg 1994; 81: 935-41.
11. Lederle FA, Wilson SE, Johnson GRJ, Reinke DB, Littooy FN, Archer CW, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346: 1437-44.
12. The UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998; 352: 1649-55.
13. Brown P, Zelt D, Sobolev B. The risk of rupture in untreated aneurysms: The impact of size, gender, and expansion rate. J Vasc Surg 2003; 37: 280-4.
14. Powell JT, Greenhalgh RM. Small abdominal aortic aneurysms. N Engl J Med 2003; 348: 1895-901.
15. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002; 360: 1531-9.
16. Darling RC. Ruptured arteriosclerotic abdominal aortic aneurysms: A pathologic and clinical study. Am J Surg 1970; 119: 379-401.
17. Van Walraven C, Mahon JL, Moher D, Bohm C, Laupacis A. Surveying physicians to determine the minimal important difference: implications for sample-size calculation. J Clin Epidemiol. 1999; 52: 717-23.
18. Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: Comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. 2002; 35: 923-9.
19. Shah PK. Inflammation, Metalloproteinases, and Increased Proteolysis: An Emerging Pathophysiological Paradigm in Aortic Aneurysm. Circulation 1997; 96: 2115-7.
20. Brophy CM, Reilly JM, Smith GJ, Tilson MD. The role of inflammation in nonspecific abdominal aortic aneurysm disease. Ann Vasc Surg 1991; 5: 229-33.
21. Wassef M, Baxter BT, Chisholm RL, Dalman RL, Fillinger MF, Heinecke J, et al. Pathogenesis of abdominal aortic aneurysms: A multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg 2001; 34: 730-8.
22. Wills A, Thompson MM, Crowther M, Sayers RD, Bell PRF. Pathogenesis of abdominal aortic aneurysms - cellular and biochemical mechanisms. Eur J Vasc Endovasc Surg 1996; 12: 391-400.
23. Tilson MD. Aortic aneurysms and atherosclerosis. Circulation 1992; 85: 378-9.
24. Davies MJ. Aortic Aneurysm Formation - Lessons from Human Studies and Experimental Models. Circulation 1998; 98: 193-5.
25. Ailawadi G, Eliason JL, Upchurch GRJ. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vasc Surg 2003; 38: 584-8.
26. Steinmetz EF, Buckley C, Thompson RW. Prospects for the medical management of abdominal aortic aneurysms. Vasc Endovascular Surg 2003; 37: 151-63.
27. Tilson MD. Regarding "Atherosclerotic aneurysm formation in an in situ saphenous vein graft". J Vasc Surg 1995; 22: 120.
28. Ward AS. Aortic aneurysmal disease. A generalized dilating diathesis. Arch Surg 1992; 127: 990-1.
29. Loftus IM, McCarthy MJ, Lloyd A, Naylor R, Bell PRF, Thompson MM. Prevalence of true vein graft aneurysms: Implications for aneurysm pathogenesis. J Vasc Surg 1999; 29: 403-8.
30. Goodall S, Crowther M, Hemingway DM, Bell PR, Thompson MM. Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 2001; 104: 304-9.
31. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995; 15: 1145-51.
32. Koch AE, Haines GK, Rizzo RJ, Radosevich JA, Pope RM, Robinson PG, et al. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol 1990; 137: 1199-213.
33. Vine N, Powell JT. Metalloproteinases in degenerative aortic disease. Clin Sci 1991; 81: 233-9.
34. Dobrin PB, Baumgartner N, Anidjar S, Chejfec G, Mrkvicka R. Inflammatory aspects of experimental aneurysms. Effect of methylprednisolone and cyclosporine. Ann N Y Acad Sci 1996; 800: 74-88.
35. Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP. Elastase induced experimental aneurysms in rats. Circulation 1990; 82: 973-81
36. Ricci MA, Strindberg G, Slaiby JM, Guibord RS, Bergersen LJ, Nicholas PP, et al. Anti-CD18 monoclonal antibody slows experimental aortic aneurysm expansion. J Vasc Surg 1996; 23: 301-7.
37. Landry D, Couper L, Bryant S, Lindner V. Activation of the NF-kB and IkB system in smooth muscle cells after rat arterial injury: induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. J Pathol 1997; 151: 1085-95.
38. Lawrence DM, Singh RS, Franklin DP, Carey DJ, Elmore JR. Rapamycin suppresses experimental aortic aneurysm growth. J Vasc Surg 2004; 40: 334-8.
39. Nakashima H, Aoki M, Miyake T, Kawasaki T, Iwai M, Jo N, et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors. Circulation 2004; 109: 132-8.
40. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, Tall A. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 1996; 271: 8837-42.
41. van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1999; 8: 252-78.
42. Rohde LE, Arroyo LH, Rifai N, Creager MA, Libby P, Ridker P, et al. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler Thromb Vasc Biol 1999; 19: 1695-9.
43. Juvonen J, Surcel H-M, Satta J, Teppo A-M, Bloigu A, Syrjälä H, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1997; 17: 2843-7.
44. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE, et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 2260-5.
45. Geba RGJ, Carey N, Davies AH. Chlamydia pneumoniae and vascular disease. Br J Surg 1998; 85: 1191-7.
46. Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor-Robinson D. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 1996; 49: 102-6.
47. Satta J, Laurila A, Paakko P, Haukipuro K, Sormunen R, Parkkila S, et al. Chronic inflammation and elastin degradation in abdominal aortic aneurysm disease: an immunohistochemical and electron microscope study. Eur J Vasc Endovasc Surg 1998; 15: 313-9.
48. Juvonen J, Juvonen T, Laurila A, Alakarppa H, Lounatmaa K, Surcel HM, et al. Demonstration of Chlamydia pneumonia in the walls of abdominal aortic aneurysms. J Vasc Surg. 1997; 25: 499-505.
49. Halme S, Juvonen T, Laurila A, Juvonen J, Mosorin M, Saikku P, et al. Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms. Eur J Clin Invest 1999; 29: 546-52.
50. Petersen E, Boman J, Persson K, Arnerlov C, Wadell G, Juto P, et al. Chlamydia pneumoniae in human abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1998; 15: 138-42.
51. Meijer A, van der Vliet JA, Roholl PJ, Gielis-Proper SK, de Vries A, Ossewaaede JM. Chlamydia pneumoniae in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1999; 19: 2680-6.
52. Lindholt JS, Juul S, Vammen JS, Henneberg EW. Immunoglobulin A antibodies against Chlamydia pneumonia are associated to expansion of abdominal aortic aneurysms. Br J Surg 1999; 86: 634-8.
53. Kol A, Suhkova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumour necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 28: 300-7.
54. Vammen JS, Lindholt JS, Ostergaard L, Fasting H, Henneberg EW. Randomised double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001; 88: 1066-72.
55. Tambiah J, Powell JT. Chlamydia pneumoniae antigens facilitate experimental aortic dilatation: prevention with azithromycin. J Vasc Surg 2002; 36: 1011-7.
56. Manning MW, Cassis LA, Daugherty A. Differential Effects of Doxycycline, a Broad-Spectrum Matrix Metalloproteinase Inhibitor, on Angiotensin II-Induced Atherosclerosis and Abdominal Aortic Aneurysms. Arterioscler Thromb Vasc Biol 2003; 23: 483-8.
57. Cohen JR, Sarfati I, Danna D, Wise L. Smooth muscle cell elastase, atherosclerosis, and abdominal aortic aneurysms. Ann Surg 1992; 216: 327-30.
58. Cohen JR, Keegan L, Sarfati I, Danna D, Ilardi C, Wise L. Neutrophil chemotaxis and neutrophil elastase in the aortic wall in patients with abdominal aortic aneurysms. J Invest Surg 1991; 4: 423-30.
59. Hobbs SD, Claridge MW, Quick CR, Day NE, Bradbury AW, Wilmink AB. LDL cholesterol is associated with small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003; 26: 618-22.
60. Gregory AK, Yin NX, Capella J, Xia KM, Newman KM, Tilson MD. Features of autoimmunity in the abdominal aortic aneurysm. Ann Surg 1996; 131: 85-8
61. van der Vliet JA, Boll APM. Abdominal aortic aneurysm. Lancet 1997; 349: 863-6.
62. Loftus IM, Thompson MM. The role of matrix metalloproteinases in vascular disease. Vasc Med 2002; 7: 117-33.
63. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degradation in an elastase-induced rat model of abdominal aortic aneurysm: Preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996; 23: 336-46.
64. Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci 1996; 800: 157-74.
65. Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin 2004; 20: 419-32.
66. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Inv 2002; 110: 625-32.
67. Thompson RW, Holmes DR, Merterns RA, Liao S, Botney MD, Mecham RP, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995; 96: 318-26.
68. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000; 105: 1641-9
69. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee R, et al. Cystatin C defiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191-7.
70. Henderson EL, Geng YJ, Sukhova GK, Whittemore AD, Knox J, Libby P. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation 1999; 99: 96-104.
71. Rowe VL, Stevens SL, Reddick TT, Freeman MB, Donnell R, Carroll RC, et al. Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human aortas. J Vasc Surg 2000; 31: 567-76.
72. Thompson RW, Liao S, Curci JA. Vascular smooth muscle cell apoptosis in abdominal aortic aneurysms. Coron Artery Dis 1997; 8: 623-31.
73. Allaire E, Muscatelli-Groux B, Mandet C, Guinault AM, Bruneval P, Desgranges P, et al. Paracrine effect of vascular smooth muscle cells in the prevention of aortic aneurysm formation. J Vasc Surg 2002; 36: 1018-26.
74. Harter L, Gross B, Callen P, Barth R. Ultrasonic evaluation of abdominal aortic thrombus. J Ultrasound Med 1982; 1: 315-8.
75. Kazi M, Thyberg J, Religa P, Roy J, Eriksson P, Hedin U, et al. Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J Vasc Surg 2003; 38: 1283-92.
76. Stenback J, Kalin B, Swedenborg J. Growth of thrombus is a better predictor for rupture than diameter in patients with abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2000; 20: 466-9.
77. Satta J, Laara E, Juvonen J. Intraluminal thrombus predicts rupture of an abdominal aortic aneurysm. J Vasc Surg 1996; 23: 737-9.
78. Vorp DA, Lee PC, Wang DHJ, Makaroun MS, Nemoto EM, Ogawa S, et al. Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. J Vasc Surg 2001; 34: 291-9.
79. Fontaine V, Jacob MP, Houard X, Rossignol P, Plissonnier D, Angles-Cano E, et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002; 161: 1701-10
80. Fontaine V, Touat Z, Mtairag E, Vranckx R, Louedec L, Houard X, et al. Role of leukocyte elastase in preventing cellular recolonization of the mural thrombus. Am J Pathol 2004; 164: 2077-87.
81. Thompson RW. Reflections on the pathogenesis of abdominal aortic aneurysms. Cardiovasc Surg 2002; 10: 389-94.
82. Hoshina K, Sho E, Sho M, Nakahashi TK, Dalman RL. Wall shear stress and strain modulate experimental aneurysm cellularity. J Vasc Surg 2003; 37: 1067-74.
83. Sho E, M S, Hoshina K, Kimura H, Nakahashi TK, Dalman RL. Hemodynamic forces regulate mural macrophage infiltration in experimental aortic aneurysms. Exp Mol Pathol 2004; 76: 108-16.
84. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994; 330: 1335-41.
85. Powell JT, Bashir A, Dawson S, Vine N, Henney AM, Humphries SE, et al. Genetic variation on chromosome 16 is associated with abdominal aortic aneurysm. Clin Sci 1990; 78: 13-6.
86. Fatini C, Pratesi G, Sofi F, Gensini F, Sticchi E, Lari B, et al. ACE DD genotype: a predisposing factor for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2005; 29: 227-32.
87. Jones KG, Powell JT, Brown LC, Greenhalgh RM, Jormsjö S, Eriksson P. The influence of 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene promoter on the incidence, growth and operative risk of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2002; 23: 421-5.
88. Holmes DR, Liao S, Parks WC, Thompson RW. Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiological implications. J Vasc Surg 1995; 21: 761-72.
89. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175-83.
90. Miller FJJ, Sharp WJ, Fang X, Oberley LW, Oberley TD, Weintraub NL. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysm remodelling. Arterioscler Thromb Vasc Biol 2002; 22: 560-5.
91. Yajima N, Masuda M, Miyazaki M, Nakajima N, Chien S, Shyy JY-J. Oxidative stress is involved in the development of experimental abdominal aneurysm: A study of the transcription profile with complementary DNA microarray. J Vasc Surg 2002; 36: 379-85.
92. Haddad J, Safieh-Garabedian B, Saade NE, Kanaan SA, Land SC. Chemioxyexcitation (delta pO2/ROS)-dependent release of IL-1beta, IL-6 and TNF-alpha: evidence of cytokines as oxygensensitive mediators in the alveolar epithelium. Cytokine 2001; 7: 138-47.
93. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Inv 1996; 98: 2572-9.
94. Li PF, Dietz R, Von Harsdorf R. Reactive oxygen species induce apoptosis of vascular smooth muscle cell. FEBS Lett 1997; 404: 249-52.
95. Simpson C, Boucek R, Nobel N. Influence of d-, l-, and dlpropranolol, and practolol on B-aminopropionitrile-induced aortic ruptures of turkeys. Toxicol Appl Pharmacol 1976; 169-75.
96. Simpson C. Sotalol for the protection of turkeys from the development of B-aminopropionitrile-induced aortic ruptures. Br J Pharmacol 1972; 45: 385-90.
97. Simpson C, Kling J, Palmer R. The use of propranolol for the protection of turkeys from the development of beta-aminopropionitrile induced aortic rupture. Angiology 1968; 19: 414-8.
98. Boucek R, Gunja-Smith Z, Nobel N, Simpson C. Modulation by propranolol of the lysyl cross-links in aortic elastin and collagen of the aneurysm-prone turkey. Biochem Pharmacol 1983; 32: 275-80.
99. Simpson CF, Boucek RJ. The B-aminopropionitrile-fed turkey: a model for detecting potential drug action on arterial tissue. Cardiovasc Res 1983; 17: 26-32
100. Brophy C, Tilson J, Tilson M. Propranolol stimulates the crosslinking of matrix components in skin from the aneurysmprone Blotchy mouse. J Surg Res 1989; 46: 330-2.
101. Brophy C, Tilson J, Tilson M. Propranolol delays the formation of aneurysms in the male blotchy mouse. J Surg Res 1988; 44: 687-9.
102. Slaiby J, Ricci M, Gadowski G, Hendley E, Pilcher D. Expansion of aortic aneurysms is reduced by propranolol in a hypertensive rat model. J Vasc Surg. 1994; 20: 178-83.
103. Moursi M, Beebe H, Messina L, Welling T, Stanley J. Inhibition of aortic aneurysm development in blotchy mice by adrenergic blockade independent of altered lysyl oxidase activity. J Vasc Surg. 1995; 21: 792-9.
104. Leach S, Toole A, Stern H, DeNatale R, Tilson M. Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Arch Surg 1988; 123: 606-9.
105. Gadowski G, Pilcher D, Ricci M. Abdominal aortic aneurysm expansion rate: Effect of size and beta-adrenergic blockade. J Vasc Surg. 1994; 19: 727-31.
106. Englund R, Hudson P, Hanel K, Stanton A. Expansion rates of small abdominal aortic aneurysms. Aust N Z J Surg. 1998; 68: 21-4.
107. Cronenwett J, Sargent S, Wall M, Hawkes M, Freeman D, Dain B, et al. Variables that affect the expansion rate and outcome of small abdominal aortic aneurysms. J Vasc Surg. 1990; 11: 260-9.
108. Tilson M. Propranolol versus placebo for small abdominal aortic aneurysms. J Vasc Surg. 1992; 15: 872-3.
109. Ricci M, Pilcher D, McBride R. Design of a trial to evaluate the effect of propranolol upon abdominal aortic aneurysm expansion. Ann N Y Acad Sci 1996; 800: 252-3.
110. Chakkour K, Gouny P, Nussaume O, Vayssairat M. Medical treatment of aortic aneurysms using beta-blockers. J Mal Vasc 1995; 20: 288-9.
111. Lindholt JS, Henneberg EW, Juul S, Fasting H. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 1999; 18: 52-7.
112. Wilmink ABM, Hubbard CSFF, Day NE, Quick CRG. Effect of propranolol on the expansion of abdominal aortic aneurysms: a randomized study. Br J Surg 2000; 87: 499.
113. The Propranolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: Results of a randomized trial. J Vasc Surg. 2002; 35: 72-9.
114. Franklin IJ, Walton LJ, Greenhalgh RM, Powell JT. The influence of indomethacin on the metabolism and cytokine secretion of human aneurysmal aorta. Eur J Vasc Endovasc Surg 1999; 18: 35-42.
115. Holmes DR, Petrinec D, Wester W, Thompson RW, Reilly JM. Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res 1996; 63: 305-9.
116. Miralles M, Wester W, Sicard GA, Thompson R, Reilly JM. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 1999; 29: 884-92.
117. Holmes DR, Wester W, Thompson RW, Reilly JM. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997; 25: 810-5.
118. Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, Taylor GW, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999; 100: 48-54.
119. Lenzer J. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. Br Med J 2005; 330: 440.
120. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. N Engl J Med 2005; 352: 1071-80.
121. European Medicines Agency. European Medicines Agency announces regulatory action on COX-2 inhibitors. European Medicines Agency Press Office 2005.
122. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003; 361: 247-9.
123. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-kB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 2001; 50: 556-65.
124. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-6.
125. Sinha S, Frishman WH. Matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target. J Clin Pharmacol 1998; 38: 1077-88.
126. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-microbial mechanisms. Adv Dent Res 1998; 12: 12-26.
127. Golub LM, Evans RT, McNamara TF, Lee HM, Ramamurthy NS. A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinase and bone loss in Porphyromonas gingivalis-induced periodontitis in rats. Ann N Y Acad Sci 1994; 732: 96-111.
128. Golub LM, Suomalainen K, Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992; 2: 80-90.
129. Ryan ME, Ashley RA. How do tetracyclines work? Adv Dent Res 1998; 12: 149-51.
130. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987; 66: 1310-4.
131. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983; 18: 516-26.
132. Uitto VJ, Firth JD, Nip L, Golub LM. Doxycycline and chemically-modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann N Y Acad Sci 1994; 732: 140-51.
133. Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumour necrosis factor-alpha and doxycycline. J Biol Chem 1997; 272: 504-9.
134. Hanemaaijer R, Viser H, Koolwijk P, Sorsa T, Salo T, Golub LM, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 1998; 12: 114-8.
135. Shlopov BV, Smith GNJ, Cole AA, Hasty KA. Differential patterns of response to doxycycline and transforming growth factor beta in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum 1999; 42: 719-27.
136. Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG, Reilly JM, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 2000; 31: 325-42.
137. Smith GNJ, Brandt KD, Hasty KA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 1996; 39: 235-44.
138. Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingham T, et al. Effects of tetracyclines on neutrophil, gingival and salivary collagenases: a functional and Western blot assessment with specific reference to their cellular sources in peridontal disease. Ann N Y Acad Sci 1994; 732: 112-31.
139. Solomon A, Rosenblatt M, Li D, Monroy D, Ji Z, Lokeshwar BL, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Opthalmol Vis Sci 2000; 41: 2544-57.
140. Liu J, Kuszynski CA, Baxter BT. Doxycycline induces Fas/Fas ligand mediated apoptosis in Jurkat T lymphocytes. Biochem Biophys Res Commun 1999; 260: 562-7.
141. Amin AA, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996; 93: 14014-9.
142. Ramamurthy NS, Vernillo AT, Greenwald RA, Lee HM, Sorsa T, Golub LM, et al. Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res 1993; 8: 1247-53.
143. Sorsa T, Lindy O, Konttinen YT, Suomalainen K, Ingman T, Saari H, et al. Doxycycline in the protection of serum alpha-1 antitrypsin from human neutrophil collagenase and gelatinase. Antimicrob Agents Chemother 1993; 37: 592-4.
144. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth, migration and matrix remodelling after arterial injury. Am J Pathol 2002; 160: 1089-95.
145. Courtman DW, Franco CD, Meng Q, Bendeck MP. Inward remodelling of the rabbit aorta is blocked by the matrix metalloproteinase inhibitor doxycycline. J Vasc Res 2004; 41: 157-65.
146. Loftus IM, Porter K, Peterson M, Boyle J, London NJ, Bell PR, et al. MMP inhibition reduces intimal hyperplasia in a human vein graft stenosis model. Ann N Y Acad Sci 1999; 878: 547-50.
147. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998; 28: 1082-93.
148. Boyle JR, McDermott E, Crowther M, Wills AD, Bell PR, Thompson MM. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg 1998; 27: 354-61.
149. Franklin IJ, Harley SL, Greenhalgh RM, Powell JT. Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis. Br J Surg 1999; 86: 771-5.
150. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann N Y Acad Sci 1999; 878: 159-78.
151. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002; 36: 1-12.
152. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34: 606-10.
153. Loftus IM, Naylor AR, Bell PRF, Thompson MM. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002; 89: 680-94.
154. Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PRF, et al. Prospective, Randomized, Double-Blind Trial Investigating the Effect of Doxycycline on Matrix Metalloproteinase Expression Within Atherosclerotic Carotid Plaques. Stroke 2002; 33: 2858-64.
155. Baxter BT. Regarding "Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study". J Vasc Surg 2001; 34: 757-8.
156. Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G, Franklin DP, Youkey JR. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg 1999; 29: 130-8.
157. Moore G, Liao S, Curci JA, Starcher BC, Martin RL, Hendricks RT, et al. Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J Vasc Surg 1999; 29: 522-32.
158. Treharne GD, Boyle JR, Goodall S, Loftus IM, Bell PRF, Thompson MM. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg 1999; 86: 1053-8.
159. Brophy CM, Sumpio B, Reilly JM, Tilson MD. Decreased tissue inhibitor of metalloproteinases (TIMP) in abdominal aortic aneurysm tissue: a preliminary report. J Surg Res 1991; 50: 653-7.
160. Cohen JR, Sarfai I, Ratner L, Tilson MD. Alpha-1 antitrypsin phenotypes in patients with abdominal aortic aneurysms. J Surg Res 1990; 49: 319-21.
161. Porter KE, Loftus IM, Peterson M, Bell PRF, London NJM, Thompson MM. Marimastat inhibits neointimal thickening in a model of human vein graft stenosis. Br J Surg 1998; 85: 1373-7.
162. Allaire E, Forough R, Clowes M, Starcher B, Clowes AW. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Inv 1998; 102: 1413-20.
163. Allaire E, Hasenstab D, Kenagy RD, Starcher B, Clowes MM, Clowes AW. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 1998; 98: 249-55.
164. Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004; 6: 96-102.
165. Carmeliet P. Proteinases in cardiovascular aneurysms and rupture: targets for therapy? J Clin Invest 2000; 105: 1519-20.
166. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-61.
167. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, et al. Angiotensin-Converting Enzyme Inhibition Prevents Arterial Nuclear Factor-{kappa}B Activation, Monocyte Chemoattractant Protein-1 Expression, and Macrophage Infiltration in a Rabbit Model of Early Accelerated Atherosclerosis. Circulation 1997; 95: 1532-41.
168. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-8.
169. Ito T, Ikeda U, Yamamoto K, Shimada K. Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Atherosclerosis 2002; 165: 51-5.
170. Nishimoto M, Takai S, Fukumoto H, Tsunemi K, Yuda A, Sawada Y, et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci 2002; 71: 2195-205.
171. Chen X-L, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II Induces Monocyte Chemoattractant Protein-1 Gene Expression in Rat Vascular Smooth Muscle Cells. Circ Res 1998; 83: 952-9.
172. Hahn A, Jonas U, Buhler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347: 178-80.
173. Chen XL, Tummala PE, Olbrych MT, Alexander RW. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83: 952-9.
174. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995; 115: 201-15.
175. Brasier AR, Recinos III A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-66.
176. Miyazaki M, Takai S. Anti-atherosclerotic effects of an angiotensin-converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol 1999; 128: 523-9.
177. Pola R, Gaetani E, Santoliquido A, Gerardino L, Cattani P, Serricchio M, et al. Abdominal aortic aneurysm in normotensive patients: association with angiotensin-converting enzyme gene polymorphism. Eur J Vasc Endovasc Surg 2001; 21: 445-9.
178. Hamano K, Ohishi M, Ueda M, Fujioka K, Katoh T, Zempo N, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is not a risk factor predisposing to abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 1999; 18: 158-61.
179. Yeung JMC, Heeley S, Gray S, Lingam MK, Manning G, Nash JR, et al. Does the angiotensin-converting enzyme (ACE) gene polymorphism affect rate of abdominal aortic aneurysm expansion? Eur J Vasc Endovasc Surg 2002; 24: 69-71.
180. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 1994; 93: 339-46.
181. Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994; 90: 449-55.
182. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, et al. Angiotensin II causes vascular hypertrophy in part by a nonpressor mechanism. Hypertension 1991; 17: 626-35.
183. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-73.
184. Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int 1993; 44: 1266-72.
185. Chrysant SG. Vascular remodelling: the role of angiotensin-converting enzyme inhibitors. Am Heart J 1998; 135: S21-30.
186. Nishijo N, Sugiyama F, Kimoto K, Taniguchi K, Murakami K, Suzuki S, et al. Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce angiotensin II. Lab Invest 1998; 78: 1059-66.
187. Daugherty A, Manning MW, Cassis LA. Angiotensin-II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-12.
188. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001; 134: 865-70.
189. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, Thompson RW. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001; 33: 1057-64.
190. Claridge MW, Hobbs SD, Quick CR, Day NE, Bradbury AW, Wilmink AB. ACE inhibitors increase type III collagen synthesis: a potential explanation for reduction in acute vascular events by ACE inhibitors. Eur J Vasc Endovasc Surg 2004; 28: 67-70.
191. Wilmink AB, Vardulaki KA, Hubbard CS, Day NE, Ashton HA, Scott AP, et al. Are antihypertensive drugs associated with abdominal aortic aneurysms? J Vasc Surg 2002; 36: 751-7.
192. Boyle JR, Loftus IM, Goodall S, Crowther M, Bell PR, Thompson MM. Amlodipine potentiates metalloproteinase activity and accelerates elastin degradation in a model of aneurysmal disease. Eur J Vasc Endovasc Surg 1998; 16: 408-14.
193. Ohishi M, Ueda M, Rakugi H, Naruko T, Kojima A, Okamura A, et al. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. J Hypertens 1999; 17: 547-53.
194. Takai S, Jin D, Muramatsu M, Miyazaki M. Chymase as a novel target for the prevention of vascular diseases. Trends Pharmacol Sci 2004; 25: 518-22.
195. Frank BT, Rossal JC, Caughey GH, Fang KC. Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase. J Immunol 2001; 166: 2783-92.
196. Saarinen J, Kalkkinen N, Welgus HG, Kovanen PT. Activation of human interstitial procollagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. J Biol Chem. 1994; 269: 18134-40.
197. Fang KC, Raymond WW, Blount JL, Caughey GH. Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem 1997; 272: 25628-35.
198. Ihara M, Hidenori U, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aneurysm. Hypertension 1998; 33: 1399-405.
199. Sasaki T, Mann K, Murphy G, Chu ML, Timpl R. Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases. Eur J Biochem 1996; 240: 427-34.
200. Tsunemi K, Takai S, Nishimoto M, Yuda A, Hasegawa S, Sawada Y, et al. Possible roles of angiotensin II-forming enzymes, angiotensin converting enzymes and chymase-like enzymes, in the human aneurysmal aorta. Hypertens Res 2002; 25: 817-22.
201. Tsunemi K, Takai S, Nishimoto M, Jin D, Sakaguchi M, Muramatsu M, et al. A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6- dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl] acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 2004; 309: 879-83.
202. Pedersen T, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
203. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
204. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47: 648-57.
205. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002; 36: 150-7.
206. Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M, Monopoli A, et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 2004; 101: 8497-502.
207. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res 1998; 83: 683-90.
208. Stalker TJ, Lefer AM, Scalia R. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitivity C-reactive protein levels. Br J Pharmacol 2001; 133: 406-12.
209. Rezaie-Majd A, Maca T, Bucek R, Valent P, Muller M, Husslein P, et al. Simvastatin reduces expression of cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-9.
210. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-8.
211. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 form vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23: 769-75.
212. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115-21.
213. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002; 22: 1452-8.
214. Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, et al. Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 2003; 57: 168-77.
215. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002; 160: 49-58.
216. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-64.
217. Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 2003; 108: 2113-20.
218. Murphy RT, Foley JB, Mulvihill N, Crean P, Walsh MJ. Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol 2001; 87: 446-8.
219. Thakur NK, Hayashi T, Sumi D, Kano H, Tsunekawa T, Iguchi A. HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide. Am J Physiol Heart Circ Physiol 2001; 281: H75-83.
220. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reducatase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-7.
221. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ, et al. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol. 2004; 287: H560-6.
222. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, et al. A HMG-CoA reductase inhibitor possesses a potent antiatherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155: 347-57.
223. Gonzalez-Fernandez F, Jimenez A, Lopez-Blaya A, Velasco S, Arriero MM, Celdran A, et al. Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. Atherosclerosis 2001; 155: 61-70.
224. Kolyada AY, Fedtsov A, Madias NE. 3-hydroxy-3-methylgluyaryl Coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. Hypertension 2001; 38: 1024-9.
225. Berkels R, Nouri SK, Taubert D, Bartels H, Roesen P, Roesen R, et al. The HMG-CoA reductase inhibitor cerivastatin enhanced the nitric acid bioavailability of the endothelium. J Cardiovasc Pharmacol 2003; 42: 356-63.
226. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitivity C-reactive protein levels. Circulation 2001; 103: 1933-5.
227. Albert MA, Danielson E, Rifai N, Ridker P. Effect of statin therapy on C-reactive protein levels. JAMA 2001; 286: 64-70.
228. März W, Winkler K, Nauck M, Böhm B, Winkelmann B. Effects of statins on C-Reactive Protein and Interleukin-6 (The Ludwigshafen Risk and Cardiovascular Health Study). Am J Cardiol 2003; 92: 305-8.
229. Kibayashi E, Urakaze M, Kobashi C, Kishida M, Takata M, Sato A, et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci 2005; 108: 512-21.
230. Swiatkowska M, Pawlowska Z, Szemraj J, Drzewoski J, Watala C, Cierniewski CS. Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by downregulation of cellular signaling and the inhibition of PAI-1 promoter activity. Jpn J Pharmacol 2002; 90: 337-44.
231. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, Cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-83.
232. Ikeda U, Shimpo M, Ohki R, Inaba H, Takahashi M, Yamamoto K, et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000; 36: 325-9.
233. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993-9.
234. Ganné F, vasse M, Beaudeux J-L, Peynet J, Francois A, Mishal Z, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherosclerosis. Thromb Haemost 2000; 84: 680-8.
235. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001; 69: 959-62.
236. Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology 2000; 59: 245-54.
237. Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S, Ishizuka N, et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36: 158-63.
238. Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle-Chavez SJ, Mao D, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005; 241: 92-101.
239. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death: implications for plaque stabilization. Circulation 2001; 103: 926-33.
240. Molloy K, Thompson MM, Schwalbe E, Bell PRF, Naylor AR, Loftus IM. Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. Am J Cardiol 2004; 94: 144-6.
241. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
242. Daskalopoulou SS, Daskalopoulou ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Medicinal Chem 2005; 12: 443-52.
243. Poldermans D, Bax JJ, Kertai MD, Krenning B, Westerhout CM, Schinkel AFL, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107: 1848-51.
244. Kertai MD, Boersma E, Westerhout CM, van Domburg R, Klein J, Bax JJ, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116: 96-103.
245. Kertai MD, Boersma E, Westerhout CM, Klein J, Van Urk H, Bax JJ, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 2004; 28: 343-52.
246. Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68: 1127-31.
247. Carrell TWG, Smith A, Burnand KG. Experimental techniques and models in the study of the development and treatment of abdominal aortic aneurysm. Br J Surg 1999; 86: 305-12.
248. Sho E, Chu J, Sho M, Fernandes B, Judd D, Ganesan P, et al. Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms. J Vasc Surg 2004; 39: 1312-21.